Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas

被引：123

作者：

Kataoka, Keisuke ^{[1
,2
]}

Miyoshi, Hiroaki ^{[3
]}

Sakata, Seiji ^{[4
]}

Dobashi, Akito ^{[4
]}

Couronne, Lucile ^{[5
,6
,7
,8
]}

Kogure, Yasunori ^{[13
]}

Sato, Yasuharu ^{[9
,10
]}

Nishida, Kenji ^{[9
]}

Gion, Yuka ^{[9
]}

Shiraishi, Yuichi ^{[11
]}

Tanaka, Hiroko ^{[11
]}

Chiba, Kenichi ^{[11
]}

Watatani, Yosaku ^{[1
]}

Kakiuchi, Nobuyuki ^{[1
]}

Shiozawa, Yusuke ^{[1
]}

Yoshizato, Tetsuichi ^{[1
]}

Yoshida, Kenichi ^{[1
]}

Makishima, Hideki ^{[1
]}

Sanada, Masashi ^{[12
]}

Onozawa, Masahiro ^{[13
]}

Teshima, Takanori ^{[13
]}

Yoshiki, Yumiko ^{[14
]}

Ishida, Tadao ^{[14
]}

Suzuki, Kenshi ^{[14
]}

Shimada, Kazuyuki ^{[15
]}

Tomita, Akihiro ^{[15
]}

Kato, Motohiro ^{[16
]}

Ota, Yasunori ^{[17
]}

Izutsu, Koji ^{[18
]}

Demachi-Okamura, Ayako ^{[19
]}

Akatsuka, Yoshiki ^{[19
,20
]}

Miyano, Satoru ^{[11
]}

Yoshino, Tadashi ^{[9
]}

Gaulard, Philippe ^{[21
,22
,23
]}

Hermine, Olivier ^{[5
,6
,7
,8
]}

Takeuchi, Kengo ^{[4
]}

Ohshima, Koichi ^{[3
]}

Ogawa, Seishi ^{[1
]}

机构：

[1] Kyoto Univ, Grad Sch Med, Dept Pathol & Tumor Biol, Kyoto, Japan

[2] Natl Canc Ctr, Div Mol Oncol, Res Inst, Tokyo, Japan

[3] Kurume Univ, Dept Pathol, Sch Med, Kurume, Fukuoka, Japan

[4] Japanese Fdn Canc Res, Inst Canc, Pathol Project Mol Targets, Tokyo, Japan

[5] Hop Necker Enfants Malad, AP HP, Dept Hematol, Paris, France

[6] INSERM, UMR 1163, Paris, France

[7] CNRS, ERL 8254, Lab Cellular & Mol Mech Hematol Disorders & Thera, Imagine Inst, Paris, France

[8] Paris Descartes Sorbonne Paris Cite Univ, Paris, France

[9] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathol, Okayama, Japan

[10] Okayama Univ, Div Pathophysiol, Grad Sch Hlth Sci, Okayama, Japan

[11] Univ Tokyo, Lab DNA Informat Anal, Ctr Human Genome, Inst Med Sci, Tokyo, Japan

[12] Nagoya Med Ctr, Dept Adv Diag, Clin Res Ctr, Nagoya, Aichi, Japan

[13] Hokkaido Univ, Dept Hematol, Fac Med, Sapporo, Hokkaido, Japan

[14] Japanese Red Cross Med Ctr, Dept Hematol, Tokyo, Japan

[15] Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan

[16] Natl Ctr Child Hlth & Dev, Dept Pediat Hematol & Oncol Res, Tokyo, Japan

[17] Toranomon Gen Hosp, Dept Pathol, Tokyo, Japan

[18] Toranomon Gen Hosp, Dept Hematol, Tokyo, Japan

[19] Aichi Canc Ctr, Div Immunol, Res Inst, Nagoya, Aichi, Japan

[20] Fujita Hlth Univ, Dept Hematol, Sch Med, Toyoake, Aichi, Japan

[21] Henri Mondor Hosp, AP HP, Dept Pathol, Creteil, France

[22] Inst Mondor Rech Biomed, INSERM, U955, Equipe 9, Creteil, France

[23] Paris Est Univ, Creteil, France

来源：

LEUKEMIA | 2019年 / 33卷 / 07期

关键词：

B-CELL LYMPHOMA; CLASSICAL HODGKIN LYMPHOMA; IMMUNE CHECKPOINT BLOCKADE; GENETIC ALTERATIONS; SOMATIC MUTATIONS; RECURRENT; PD-L1; REARRANGEMENTS; PEMBROLIZUMAB; EXPRESSION;

D O I：

10.1038/s41375-019-0380-5

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Viral infection induces potent cellular immunity and activated intracellular signaling, which may dictate the driver events involved in immune escape and clonal selection of virus-associated cancers, including Epstein-Barr virus (EBV)-positive lymphomas. Here, we thoroughly interrogated PD-L1/PD-L2-involving somatic aberrations in 384 samples from various lymphoma subtypes using high-throughput sequencing, particularly focusing on virus-associated lymphomas. A high frequency of PD-L1/PD-L2-involving genetic aberrations was observed in EBV-positive lymphomas [33 (22%) of 148 cases], including extranodal NK/T-cell lymphoma (ENKTL, 23%), aggressive NK-cell leukemia (57%), systemic EBV-positive T-cell lymphoproliferative disorder (17%) as well as EBV-positive diffuse large B-cell lymphoma (DLBCL, 19%) and peripheral T-cell lymphoma-not otherwise specified (15%). Predominantly causing a truncation of the 3'-untranslated region, these alterations represented the most prevalent somatic lesions in ENKTL. By contrast, the frequency was much lower in EBV-negative lymphomas regardless of histology type [12 (5%) of 236 cases]. Besides PD-L1/PD-L2 alterations, EBV-positive DLBCL exhibited a genetic profile distinct from EBV-negative one, characterized by frequent TET2 and DNMT3A mutations and the paucity of CD79B, MYD88, CDKN2A, and FAS alterations. Our findings illustrate unique genetic features of EBV-associated lymphomas, also suggesting a potential role of detecting PD-L1/PD-L2-involving lesions for these lymphomas to be effectively targeted by immune checkpoint blockade.

引用

页码：1687 / 1699

页数：13

共 50 条

[31] Role of DNA methylation in the development of Epstein-Barr virus-associated gastric carcinoma [J].

Saito, Mari ;

Nishikawa, Jun ;

Okada, Toshiyuki ;

Morishige, Akihiro ;

Sakai, Kouhei ;

Nakamura, Munetaka ;

Kiyotoki, Shu ;

Hamabe, Kouichi ;

Okamoto, Takeshi ;

Oga, Atsunori ;

Sasaki, Kohsuke ;

Suehiro, Yutaka ;

Hinoda, Yuji ;

Sakaida, Isao .

JOURNAL OF MEDICAL VIROLOGY, 2013, 85 (01) :121-127

[32] Select Epstein-Barr Virus-Associated Digestive Tract Lesions for the Practicing Pathologist [J].

Alruwaii, Zainab, I ;

Montgomery, Elizabeth A. .

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2021, 145 (05) :562-570

[33] Programmed Cell Death Protein 1 Blockade Elicits Ongoing Remission in 2 Cases of Refractory Epstein-Barr Virus-Associated Metastatic Gastric Carcinoma [J].

Masetti, Michael ;

Lindinger, Martin ;

Lorenzen, Sylvie .

ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06) :375-379

[34] Epstein-Barr Virus-Associated Classical Hodgkin Lymphoma and Its Therapeutic Strategies [J].

Lee, Im-Soon .

BIOMOLECULES & THERAPEUTICS, 2011, 19 (04) :398-410

[35] microRNA profiling in Epstein-Barr virus-associated B-cell lymphoma [J].

Imig, Jochen ;

Motsch, Natalie ;

Zhu, Jia Yun ;

Barth, Stephanie ;

Okoniewski, Michal ;

Reineke, Tanja ;

Tinguely, Marianne ;

Faggioni, Alberto ;

Trivedi, Pankaj ;

Meister, Gunter ;

Renner, Christoph ;

Graesser, Friedrich A. .

NUCLEIC ACIDS RESEARCH, 2011, 39 (05) :1880-1893

[36] The Role of LMP1 in Epstein-barr Virus-associated Gastric Cancer [J].

Huang, Xinqi ;

Zhang, Meilan ;

Zhang, Zhiwei .

CURRENT CANCER DRUG TARGETS, 2024, 24 (02) :127-141

[37] Clinicopathologic Characteristics of Epstein-Barr Virus-Associated Gastric Cancer Over the Past Decade in Japan [J].

Yanagi, Ayaka ;

Nishikawa, Jun ;

Shimokuri, Kanami ;

Shuto, Takuya ;

Takagi, Tatsuya ;

Takagi, Fumiya ;

Kobayashi, Yuki ;

Yamamoto, Misa ;

Miura, Osamu ;

Yanai, Hideo ;

Suehiro, Yutaka ;

Yamasaki, Takahiro ;

Yoshiyama, Hironori ;

Sakaida, Isao .

MICROORGANISMS, 2019, 7 (09)

[38] Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma [J].

Ahmed, Mona M. ;

Gebriel, Manar G. ;

Morad, Emad A. ;

Saber, Ibrahim M. ;

Elwan, Amira ;

Salah, Mona ;

Fakhr, Ahmed E. ;

Shalaby, Amany M. ;

Alabiad, Mohamed A. .

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (06) :401-408

[39] Pathogenesis of virus-associated human cancers: Epstein-Barr virus and hepatitis B virus as two examples [J].

Chang, Kung-Chao ;

Chang, Yao ;

Wang, Lily Hui-Ching ;

Tsai, Hung-Wen ;

Huang, Wenya ;

Su, Ih-Jen .

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2014, 113 (09) :581-590

[40] Outlooks on Epstein-Barr virus associated gastric cancer [J].

Naseem, Madiha ;

Barzi, Afsaneh ;

Brezden-Masley, Christine ;

Puccini, Alberto ;

Berger, Martin D. ;

Tokunaga, Ryuma ;

Battaglin, Francesca ;

Soni, Shivani ;

McSkane, Michelle ;

Zhang, Wu ;

Lenz, Heinz-Josef .

CANCER TREATMENT REVIEWS, 2018, 66 :15-22

← 1 2 3 4 5 →